Specialty biologic drug coverage under Medicare Part D: The experience of beneficiaries with rheumatoid arthritis (RA) and multiple sclerosis (MS)

被引：0
|
作者：
Polinski, Jennifer M. [1 ,3 ]
Mohr, Penny E. [2 ]
Johnson, Lorraine [2 ]
机构：
[1] Brigham & Womens Hosp, Div Pharmaocoepidemiol & Pharmacoecon, Boston, MA 02115 USA
[2] CMS, Off Res Dev & Informat, Baltimore, MD USA
[3] Harvard Univ, Sch Med, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2008年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
068
引用
收藏
页码：S30 / S30
页数：1
相关论文
共 32 条
  • [21] PRESCRIPTION DRUG COVERAGE TYPE, OUT-OF-POCKET SPENDING, AND COST-RELATED NONADHERENCE AMONG MEDICARE BENEFICIARIES WITH RHEUMATOID ARTHRITIS
    Zheng, D.
    Thomas, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S230 - S230
  • [22] Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D
    Yazdany, Jinoos
    Dudley, R. Adams
    Lin, Grace A.
    Chen, Randi
    Tseng, Chien-Wen
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (09): : 931 - 933
  • [23] Changes in antipsychotic medication use under Medicare Part D among elderly without prior drug coverage
    Polinski, Jennifer
    Patrick, Amanda
    Levin, Raisa
    Shrank, William
    Pedan, Alex
    Varasteh, Laleh
    Schneeweiss, Sebastian
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S97 - S98
  • [24] Closing the Medicare Doughnut Hole Changes in Prescription Drug Utilization and Out-of-Pocket Spending Among Medicare Beneficiaries With Part D Coverage After the Affordable Care Act
    Tehrani, Ali Bonakdar
    Cunningham, Peter J.
    [J]. MEDICAL CARE, 2017, 55 (01) : 43 - 49
  • [25] Immunogenicity of a human TNFR55-IgG1 fusion protein (lenercept) in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients
    Christen, U
    Thuerkauf, R
    Stevens, R
    Lesslauer, W
    [J]. ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S58 - S58
  • [26] Falling into the doughnut hole: Drug spending among beneficiaries with end-stage renal disease under medicare Part D plans
    Patel, Uptal D.
    Davis, Matthew M.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (09): : 2546 - 2553
  • [27] THE EFFECT OF THE MEDICARE PART D COVERAGE GAP AND OUT-OF-POCKET BURDEN ON THE USE OF DISEASE MODIFYING DRUGS TO TREAT MULTIPLE SCLEROSIS
    Banahan, B. F., I
    Datar, M.
    Mendonca, C. M.
    Shahpurwala, Z.
    Bentley, J. P.
    Phillips, A. L.
    Stewart, M.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A211 - A211
  • [28] High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia
    Doshi, Jalpa A.
    Li, Pengxiang
    Huo, Hairong
    Pettit, Amy R.
    Kumar, Rishab
    Weiss, Brendan M.
    Huntington, Scott F.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 (04): : S78 - +
  • [29] Reducing Out-of-Pocket Cost Barriers to Specialty Drug Use Under Medicare Part D: Addressing the Problem of "Too Much Too Soon"
    Doshi, Jalpa A.
    Li, Pengxiang
    Pettit, Amy R.
    Dougherty, J. Samantha
    Flint, Ashley
    Ladage, Vrushabh P.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2017, 23 (03): : S39 - +
  • [30] REDUCING OUT-OF-POCKET COST BARRIERS TO SPECIALTY DRUG USE UNDER MEDICARE PART D: ADDRESSING THE PROBLEM OF "TOO MUCH TOO SOON"
    Doshi, J. A.
    Li, P.
    Pettit, A. R.
    Dougherty, J. S.
    Flint, A.
    Ladage, V. P.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A28 - A28
1234